MPO and breast cancer: Similarly, another study showed higher serum levels of MPO at 3 months of treatment compared to the baseline (p < 0.05) in a multicenter cohort of 78 HER2+ breast cancer patients treated with adjuvant doxorubicin, taxanes, and trastuzumab [105].